Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the potential of fenfluramine from UCB for patients with CDKL5 Deficiency Disorder and Epilepsy.

Ticker(s): UCBJF

Who's the expert?

Institution: Thomas Jefferson University

Adjunct Professor of epileptology at Thomas Jefferson Unviersity.
Currently manages 5 patients with CDKL5 deficiency.
Has published more than 350 papers and 12 books about various aspects of epilepsy.

Interview Goal

This call will be evaluating the current epilepsy treatment landscape for CDKL5 Deficiency Disorder (CDD), focusing on UCB’s fenfluramine (Fintepla) as an adjunctive therapy, its mechanism in reducing seizures, safety profile from the GEMZ Phase 3 trial, and potential impact on patient outcomes and quality of life.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.